AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35396138 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy with simultaneous integrated focal boost to intra-prostatic tumor lesions up to a total dose of 108-119 Gy (EQD2, α/β = 3 Gy)
Number of subjects: 101
Study 35396138 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy with simultaneous integrated focal boost
Number of subjects: 101
Study 35396177 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST)
Number of subjects: 118
Study 35396177 — intervention group
Group type: EXPERIMENTAL
Intervention: sit-to-stand test (STST)
Number of subjects: 118
Study 35396282 — intervention group
Group type: COMPARATOR
Intervention: Medical Treatment (MT)
Number of subjects: 971
Study 35396282 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 971
Study 35396282 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 971
Study 35396296 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Standards-based online questionnaire
Number of subjects: 600
Study 35396312 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-creation of a health plan and support via a digital platform
Number of subjects: 19
Study 35396312 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform support
Number of subjects: 19
Study 35396316 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced MRI techniques (Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours and Luminal Water imaging)
Number of subjects: 0
Study 35396316 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis from biopsy or prostatectomy
Number of subjects: 0
Study 35396812 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 250mcg daily with carboplatin AUC5-6 and paclitaxel 80 mg/m²
Number of subjects: 43
Study 35396812 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 250mcg on a 3- or 7-day schedule with carboplatin AUC6 and paclitaxel 80 mg/m²
Number of subjects: 43
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary findings (SF) offered as part of clinical exome sequencing (ES)
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical categories of secondary findings (H-SF)
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining secondary findings (SF)
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for accepting SF
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for declining SF
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesitancy about receiving secondary findings
Number of subjects: 190
Study 35396980 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication approaches regarding SF decisions
Number of subjects: 190
Study 35397092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 and 2 weeks
Number of subjects: 0
Study 35397434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatipotuzumab (1400 mg every 2 weeks) combined with tomuzotuximab (1200 mg every 2 weeks)
Number of subjects: 52
Study 35397574 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK-Cph intervention
Number of subjects: 48
Study 35397575 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Number of subjects: 0
Study 35397575 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care
Number of subjects: 0
Study 35397804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy at 40 Gy in 15 fractions or 42.72 Gy in 16 fractions followed by skin-sparing mastectomy and DIEP flap reconstruction
Number of subjects: 33
Study 35397804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 33
Study 35397804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy followed by skin-sparing mastectomy and DIEP flap reconstruction
Number of subjects: 33
Study 35397828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 16
Study 35397828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 16
Study 35397828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 35397828 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16
Study 35397952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus docetaxel and prednisone
Number of subjects: 104
Study 35398007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0
Study 35398007 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (surgery)
Number of subjects: 0
Study 35398007 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 0
Study 35398007 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 35398201 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlanders with chronic mountain sickness (CMS+)
Number of subjects: 30
Study 35398201 — intervention group
Group type: COMPARATOR
Intervention: Highlanders without chronic mountain sickness (CMS-)
Number of subjects: 30
Study 35398201 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlanders (CMS+ and CMS-)
Number of subjects: 30
Study 35398201 — intervention group
Group type: COMPARATOR
Intervention: Lowlanders
Number of subjects: 30
Study 35398584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor after cesarean delivery of nonvertex second twins
Number of subjects: 236
Study 35398584 — intervention group
Group type: COMPARATOR
Intervention: Trial of labor after cesarean delivery of vertex second twins
Number of subjects: 236
Study 35398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum albumin levels in children with severe malnutrition
Number of subjects: 242
Study 35398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of extracellular matrix (ECM) degradation
Number of subjects: 242
Study 35398787 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-dependent mechanisms
Number of subjects: 242
Study 35398787 — intervention group
Group type: EXPERIMENTAL
Intervention: ECM integrity
Number of subjects: 242
Study 35398844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiccups
Number of subjects: 1
Study 35398844 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breaths
Number of subjects: 1
Study 35399055 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive primary care intervention
Number of subjects: 779
Study 35399055 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 779
Study 35399083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile brain perfusion ultrasound (BPU) using SONAS® device
Number of subjects: 12
Study 35399240 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of IPN (expected n=94)
Number of subjects: 1253
Study 35399240 — intervention group
Group type: COMPARATOR
Intervention: Follow-up group (expected n=282)
Number of subjects: 1253
Study 35399565 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensionally printed navigational template-guided fine-needle aspiration (FNA)
Number of subjects: 18
Study 35399676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency (VAD) group
Number of subjects: 976
Study 35399676 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal vitamin A deficiency (MVAD) group
Number of subjects: 976
Study 35399676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A normal (NVA) group
Number of subjects: 976
Study 35399676 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 976
Study 35399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 230
Study 35399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Free leptin index
Number of subjects: 230
Study 35399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between fat mass and free leptin index
Number of subjects: 230
Study 35399927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between fat mass and adiponectin
Number of subjects: 230
Study 35399955 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and trajectories of the triglyceride-glucose (TyG) index
Number of subjects: 1815
Study 35399955 — intervention group
Group type: EXPERIMENTAL
Intervention: High and very high TyG index trajectories
Number of subjects: 1815
Study 35399955 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index quartile characterization
Number of subjects: 1815
Study 35399955 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 1815
Study 35400203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tortuous group (extracranial or cavernous ICA tortuosity)
Number of subjects: 370
Study 35400203 — intervention group
Group type: COMPARATOR
Intervention: Nontortuous group
Number of subjects: 370
Study 35400203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tortuous group
Number of subjects: 370
Study 35400633 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban treatment
Number of subjects: 858
Study 35400997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1505
Study 35400997 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1505
Study 35401389 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training during chemotherapy
Number of subjects: 126
Study 35401389 — intervention group
Group type: COMPARATOR
Intervention: First line chemotherapy without exercise training
Number of subjects: 126
Study 35401418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation (TPS)
Number of subjects: 30
Study 35401418 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 30
Study 35402241 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200mg or 300mg per day) for two cycles (4 weeks/cycle)
Number of subjects: 53
Study 35402359 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) during immunization
Number of subjects: 30
Study 35402359 — intervention group
Group type: COMPARATOR
Intervention: Usual care without VR
Number of subjects: 30
Study 35402736 — intervention group
Group type: EXPERIMENTAL
Intervention: READyR Program
Number of subjects: 11
Study 35402894 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Number of subjects: 178
Study 35402894 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Number of subjects: 178
Study 35402894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 35402913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus radiotherapy plus temozolomide (NIVO+RT+TMZ)
Number of subjects: 136
Study 35402913 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus radiotherapy (NIVO+RT)
Number of subjects: 136
Study 35403243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1150
Study 35403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Card Sort, Second Edition (ACS)
Number of subjects: 47
Study 35403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Dimensional Fatigue Inventory
Number of subjects: 47
Study 35403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity Functional Scale
Number of subjects: 47
Study 35403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Extremity Functional Index
Number of subjects: 47
Study 35403374 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF (n=137)
Number of subjects: 547
Study 35403446 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop on the Screening Tool for Autism in Toddlers
Number of subjects: 69
Study 35403446 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the Screening Tool for Autism in Toddlers
Number of subjects: 69
Study 35403503 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT elevation
Number of subjects: 233
Study 35403503 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP elevation
Number of subjects: 233
Study 35403503 — intervention group
Group type: COMPARATOR
Intervention: Pathological findings on CMR
Number of subjects: 233
Study 35403679 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant long-COVID fatigue
Number of subjects: 141
Study 35403679 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise heart rate
Number of subjects: 141
Study 35403679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen consumption per kilogram
Number of subjects: 141
Study 35403679 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-COVID memory impairment
Number of subjects: 141
Study 35403786 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling procedures (4 monthly sessions)
Number of subjects: 35
Study 35403818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pancreatic islet-lung transplantation
Number of subjects: 10
Study 35403852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 3968
Study 35403852 — intervention group
Group type: COMPARATOR
Intervention: Non-PVI
Number of subjects: 3968
Study 35404075 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 100 mg BID
Number of subjects: 0
Study 35404075 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 50 mg BID
Number of subjects: 0
Study 35404075 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 25 mg BID
Number of subjects: 0
Study 35404075 — intervention group
Group type: COMPARATOR
Intervention: Optimized Background Regimen (OBR)
Number of subjects: 0
Study 35404255 — intervention group
Group type: EXPERIMENTAL
Intervention: PACO service for 8 weeks
Number of subjects: 32
Study 35404255 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 32
Study 35404384 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss HCVree Trial
Number of subjects: 4641
Study 35404384 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss HCVree Post screen
Number of subjects: 4641
Study 35404384 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV incidence
Number of subjects: 4641
Study 35404402 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib (MRTX849) 600 mg twice daily
Number of subjects: 2
Study 35404402 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib (MRTX849)
Number of subjects: 2
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive weight (EW), BMI ≥25
Number of subjects: 56
Study 35404455 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (NW), BMI <25
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration ≥9 months
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) insulin concentrations
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) leptin concentrations
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental feeding restriction
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 56
Study 35404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating index (HEI)
Number of subjects: 56
Study 35404683 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET)
Number of subjects: 2290
Study 35404683 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding systemic treatment by both RS and ET response
Number of subjects: 2290
Study 35404977 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based cross-sectional study with self-reported survey and oral fluid testing for HIV antibodies.
Number of subjects: 0
Study 35405009 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 35405009 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 0
Study 35405009 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 inhibitors
Number of subjects: 0
Study 35405009 — intervention group
Group type: COMPARATOR
Intervention: PRRX2-related gene signature
Number of subjects: 0
Study 35405360 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with low PD-L1 expression (TPS < 50%)
Number of subjects: 128
Study 35405360 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with high PD-L1 expression (TPS ≥ 50%)
Number of subjects: 128
Study 35405725 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous capnography and pulse oximetry monitoring
Number of subjects: 1335
Study 35406387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs) composed of gene-regulatory small interfering (si)RNA
Number of subjects: 0
Study 35406387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs) carrying unmethylated CpG-rich oligonucleotides
Number of subjects: 0
Study 35406387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs)
Number of subjects: 0
Study 35406491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy CA27.29 assessment
Number of subjects: 3754
Study 35406491 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy CA27.29 assessment
Number of subjects: 3754
Study 35406565 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 338
Study 35406565 — intervention group
Group type: COMPARATOR
Intervention: Entrectinib
Number of subjects: 338
Study 35406565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 338
Study 35406806 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccination
Number of subjects: 0
Study 35407553 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg daily for 23 patients, 30 mg daily for 2 patients)
Number of subjects: 25
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1274
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed physician visits
Number of subjects: 1274
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in sleep time
Number of subjects: 1274
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in screen time
Number of subjects: 1274
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in physical activity
Number of subjects: 1274
Study 35409640 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress (Kessler-6 score ≥ 5)
Number of subjects: 1274
Study 35409640 — intervention group
Group type: COMPARATOR
Intervention: Urban living place
Number of subjects: 1274
Study 35409640 — intervention group
Group type: COMPARATOR
Intervention: Worse self-reported mental health
Number of subjects: 1274
Study 35409640 — intervention group
Group type: COMPARATOR
Intervention: K6 score ≥ 5
Number of subjects: 1274
Study 35410115 — intervention group
Group type: EXPERIMENTAL
Intervention: Left uterine displacement (LUD) during baseline with spinal anesthesia (SA)
Number of subjects: 46
Study 35410115 — intervention group
Group type: COMPARATOR
Intervention: Baseline without left uterine displacement (LUD)
Number of subjects: 46
Study 35410115 — intervention group
Group type: EXPERIMENTAL
Intervention: After spinal anesthesia with left uterine displacement (LUD)
Number of subjects: 46
Study 35410115 — intervention group
Group type: COMPARATOR
Intervention: After spinal anesthesia without left uterine displacement (LUD)
Number of subjects: 46
Study 35410197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 150 mg once monthly for 1 year
Number of subjects: 120
Study 35410310 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adverse childhood experiences (ACE) before the age of 18
Number of subjects: 5000
Study 35410326 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown partner HIV status
Number of subjects: 8086
Study 35410326 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of alcohol/drugs prior to intercourse (sometimes)
Number of subjects: 8086
Study 35410326 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of alcohol/drugs prior to intercourse (always)
Number of subjects: 8086
Study 35410326 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HIV treatment literacy
Number of subjects: 8086
Study 35410325 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 blockade
Number of subjects: 0
Study 35410449 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMDA (Cognition in Movement Disorders Assessment)
Number of subjects: 500
Study 35410449 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMDA-ML (Quadratic Discriminant Analysis algorithm)
Number of subjects: 500
Study 35410894 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative initial management in 78% of patients
Number of subjects: 389
Study 35410894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge
Number of subjects: 389
Study 35410894 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 intramural haematoma (IMH)
Number of subjects: 389
Study 35410894 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal vessel involvement
Number of subjects: 389
Study 35410894 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of hypothyroidism
Number of subjects: 389
Study 35410912 — intervention group
Group type: EXPERIMENTAL
Intervention: Body iron stores (BIS) measured by serum ferritin and serum transferrin receptor
Number of subjects: 789
Study 35410912 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smoking, hypertension, and increased resting heart rate
Number of subjects: 789
Study 35410912 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 789
Study 35410913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic microvascular resistance (HMR) in lesions with FFR>0.80 and CFR<2.0 (n=99)
Number of subjects: 430
Study 35410913 — intervention group
Group type: COMPARATOR
Intervention: Hyperemic microvascular resistance (HMR) in lesions with FFR≤0.80 and CFR≥2.0 (n=68)
Number of subjects: 430